MARKET

ALXO

ALXO

Alx Oncology Holdings Inc
NASDAQ
2.450
-0.150
-5.77%
After Hours: 2.440 -0.01 -0.41% 19:17 02/20 EST
OPEN
2.590
PREV CLOSE
2.600
HIGH
2.600
LOW
2.380
VOLUME
498.22K
TURNOVER
--
52 WEEK HIGH
2.660
52 WEEK LOW
0.4040
MARKET CAP
321.43M
P/E (TTM)
-1.2161
1D
5D
1M
3M
1Y
5Y
1D
ALX Oncology Leadership to Present at TD Cowen 46th Annual Health Care Conference
Reuters · 1d ago
ALX Oncology Holdings Inc. published an update to their financial calendar
Reuters · 1d ago
Press Release: ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
Dow Jones · 1d ago
Weekly Report: what happened at ALXO last week (0209-0213)?
Weekly Report · 4d ago
Weekly Report: what happened at ALXO last week (0202-0206)?
Weekly Report · 02/09 09:54
ALX Oncology Is Maintained at Overweight by Piper Sandler
Dow Jones · 02/05 15:56
Piper Sandler Maintains Overweight on ALX Oncology Holdings, Raises Price Target to $4
Benzinga · 02/05 15:46
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 02/05 12:05
More
About ALXO
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.

Webull offers ALX Oncology Holdings Inc stock information, including NASDAQ: ALXO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALXO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALXO stock methods without spending real money on the virtual paper trading platform.